Kinaxo Extends its Collaboration with Roche
KINAXO's phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using stateoftheart quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.
KINAXO Biotechnologies is a privatelyheld biotechnology service company based in Munich/Martinsried, Germany. KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug modeofaction analysis, cellular target profiling, target deconvolution, and drug repositioning.
KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.